top of page
Search

Atova's October Regulatory Roundup!

Writer: Atova
Atova
Nov 9
23 min read

✨ Welcome to the October 2026 edition of the Atova Regulatory Roundup! As we move further into autumn, it’s been another fast-paced month for the Atova team, with exciting progress, fresh scientific contributions, and speaking engagements at industry events. In this edition, we’re sharing our latest company highlights, including our team's recent travels across Europe and Asia, the final webinar of our Navigating Novel Foods masterclass series, team publications, a new Atova Insights article and some very exciting news… Along with our own news, we’ve rounded up key regulatory developments from around the globe to keep you informed 🌱 




FOctober has been a busy month for the Atova team, with opportunities to catch up together in Barcelona, celebrate new publications by the team, and connect with the wider food-tech and regulatory community across Europe and Asia!  

 

From Brussels to Singapore, our team has been out and about attending events, sharing insights and building connections across the industry. But that's not the only exciting conference news we have to share... 👀  

 

Navigating Novel Foods: EU Dossier Masterclass – Join us for the final session! 

Our Navigating Novel Foods: EU Dossier Masterclass series is approaching its final session, and registration is now open! 

 

On Thursday 26 November 2026 at 15:00 CET, join Dr Fernando Rivero Pino, Regulatory Scientist and Toxicologist at Atova, for the fourth and final part of the series. 

This session will explore the key considerations for the safety sections of an EU novel food dossier, covering ADME, toxicology, allergenicity and EFSA expectations. Fernando will discuss how to approach these areas, navigate common challenges and prepare for questions or requests for additional data during the assessment process. 

Whether you're developing a new novel food application or refining an existing dossier, this is an opportunity to gain practical insights into preparing robust safety data and navigating the EFSA novel food assessment process. 

 

Don't miss the final session of the series – register your place here! 



SAVE THE DATE: Regulating the Future of Food Conference is back! 

We’re excited to announce that the Regulating the Future of Food Conference will return on 14–15 April 2027, and we’re heading back to where it all began: Barcelona!  🌱  

 

Once again, we’ll be joining forces with our friends at Vireo Advisors to bring together voices from across the food innovation and regulatory landscape to explore the challenges shaping the industry, and what lies ahead for the future of food.  

 

We’re already working on an exciting programme of talks, workshops and opportunities to connect with regulators, risk assessors, novel food experts and others working at the forefront of food innovation. More details are coming soon, and we can’t wait to share what we have planned!  

 

Register your interest here to receive updates and be the first to know when tickets become available. We’re looking forward to seeing lots of you there! Barcelona 2027, here we come!




Atova's Latest Insights Article is Live!

The latest Atova Insights piece is live! This time Atova Regulatory Scientist, Sarah Harrison, breaks down everything you need to know about the EU Article 4 Novel Food Consultation process. If you are looking to market a food or food ingredient in the European Union and remain unsure whether it falls within the scope of the Novel Food Regulation, then this article is for you. Here Sarah outlines the Article 4 Consultation process, the advantages and disadvantages, and presents an analysis of the recent novel food consultations and their outcomes. 

 

Explore the article here. 


FEASTS Conference   

At the recent FEASTS conference in Brussels, Atova Regulatory Scientist Dr Oana Kubinyecz contributed to the discussion as part of the panel discussing Ecosystem Perspectives, and brought insights into current guidelines across key jurisdictions and highlighted how clear, transparent frameworks are essential for building consumer trust and bringing novel foods to market. Speaking as part of the "Ecosystem Perspectives: Regulation at the Service of the Consumer" session, Oana explored current guidelines across key jurisdictions and highlighted how clear, transparent frameworks are essential for building consumer trust and bringing novel foods to market. 



Foodtech Co-Creation Seminar & Japan Cell-Ag-Ready  

On the 8-9th October Hannah travelled to Japan where she spoke at the Foodtech Co-Creation Seminar with Hokkaido’s Food Industry in Sapporo. This seminar explored the current landscape for cultivated foods and precision fermentation, as well as opportunities for collaboration with Hokkaido’s food industry, including approaches to intellectual property and protecting producers’ rights. Hannah joined Dr Joshua Ravenhill (FSA), Kimberly Ong (Vireo Advisors), and David Ettinger (Keller and Heckman) for a panel discussion on ‘Overview of Policy and Technology Trends in the Foodtech Sector Overseas’. Afterwards Hannah spoke at the Japan Cell-Ag Ready Dialogue, an event that brought together regulatory scientists and experts from Korea, China, Europe, the US and Japan to share the latest developments in the safety assessment and industrial development of cultivated foods. Hannah's discussion focused on the 'Latest Discussions on Food Safety’, exploring some of the key regulatory and safety considerations shaping the cultivated food sector. 

 

Singapore International Agri-Food Week  

Hannah attended the Singapore Food Agency (SFA) Roundtable on Novel Food Regulations on 26th October, held as part of the Singapore International Agri-Food Week (SIAW). The event brought together regulators, risk assessors, researchers and industry representatives to discuss emerging developments in novel foods and global regulatory frameworks, and the role of stakeholder dialogue in building trust and supporting greater international regulatory alignment.  

 

Future of Protein Production and the Cultured Meat Symposium 

Hannah is just back from another amazing instalment of the FPP x CMS conference in Amsterdam. During the conference she teamed up with Matthijs Verstraeten from RIC for “Beyond the Burger: Uncovering Residuals in Cultivated Meat Through Analytics”, where they discussed how analytical testing can identify residual substances and support robust novel food dossiers. Hannah also joined Patricia Romero Fernández (EFSA), Valeria Teloni (Mosa Meat), Marnie Hewat (Alternative Proteins Association) and Stoffer Loman (NutriClaim) for “Inside the EU – EFSA Applications and Learnings” sharing the Atova team´s practical experience of navigating novel food applications, preparing dossiers and responding to regulatory questions. A big thank you to Nick, Seb and the entire FPP team for pulling off another fantastic event and bringing the industry together. 


be heading to Japan to speak at the Foodtech Co-Creation Seminar with Hokkaido’s Food Industry in Sapporo. The seminar will explore the current landscape for cultivated foods and precision fermentation, as well as opportunities for collaboration with Hokkaido’s food industry, including approaches to intellectual property and protecting producers’ rights. Organised by the Hokkaido Bureau of Economy, Trade and Industry (METI) and the Japan Association for Cellular Agriculture (JACA), the event will bring together experts from across the foodtech and regulatory landscape. Hannah will join Dr Joshua Ravenhill (FSA), Kimberly Ong (Vireo Advisors), and David Ettinger (Keller and Heckman) for a panel discussion on ‘Overview of Policy and Technology Trends in the Foodtech Sector Overseas’. 

 

Japan Cell-Ag-Ready | Japan | 9 October 

From Sapporo, Hannah will make her way to Tokyo to speak at the Japan Cell-Ag Ready Dialogue. The event will bring together regulatory scientists and experts from Korea, China, Europe, the US and Japan to share the latest developments in the safety assessment and industrial development of cultivated foods, as well as discuss how these emerging technologies can be effectively communicated. 

Hannah will join Dr Satoshi Kitajima, Kimberly Ong, and Ryan Simon for a panel discussion on ‘Latest Discussions on Food Safety’, exploring some of the key regulatory and safety considerations shaping the cultivated food sector. 

 

Singapore International Agri-Food Week (SIAW) | Singapore | 26–29 October 

Later in October, Hannah will be attending Singapore International Agri-Food Week (SIAW), one of the region's leading agri-food events. Bringing together policymakers, researchers, investors, entrepreneurs, food producers and industry leaders, the conference provides a platform to explore emerging technologies, strengthen food security and climate resilience, and shape the future of food production across Asia and beyond. As part of SIAW, Hannah will be attending the Asia-Pacific Agri-Food conference, which will focus on discussions examining how AI‑first R&D and biomanufacturing are reshaping agtech and foodtech innovation ecosystems. 

 

The Future of Protein Production | Amsterdam | 4–5 November 

Rounding off a busy few months, Hannah Lester will be taking to the stage at the Future of Protein Production conference x Cultured Meat Symposium in Amsterdam. Hannah will be speaking on day two of the conference alongside Marnie Hewat, Valeria Teloni, Nicolas Morin-Forest and Stoffer Loman where they will share their experiences navigating the European approval pathway. The discussion will explore what it really takes to prepare for an EU novel food application, from safety data and scientific validation to EFSA expectations, regulatory strategy, and the practical realities of submission.

 



Cultivated Meat Bioprocessing: An End-to-end Production Chain Prospective  

We’re delighted to celebrate the publication of Cultivated Meat Bioprocessing: An End-to-end Production Chain Prospective, published by Springer, with five members of the Atova team contributing to the book: Fernando Rivero Pino, Diana Rueda, PhD, Chee-Seng Hee, Oana Kubinyecz, PhD, and Hannah Lester!  


Their chapter, “Safety Aspects of Cell Culture-Derived Food for Human Consumption, ” provides a practical, end-to-end look at the safety assessment of cultivated foods, from cell sourcing and cell-line establishment through culture media, scale-up, compositional analysis, nutrition, toxicology and allergenicity. It highlights an important principle for cultivated-food developers: safety and regulatory considerations need to be built into development from the earliest stages. The goal is to generate the right evidence, at the right stage, using approaches that can help support a clearer and more robust path towards regulatory approval.   


We’re proud to see the scientific and regulatory expertise within the Atova team contributing to this growing body of knowledge and helping address some of the key questions facing the cultivated food industry. 🔬   


Want to learn more about the chapter and key safety considerations behind cultivated food development?  Read our summary exploring the publication, the key topics covered and what they mean for developers.

 

Learn more about the book here.



New publication on Rethinking Safety Assessments for Cultivated Foods 

We’re excited to see the publication of a new review exploring the role of animal toxicological studies in the safety assessment of cultivated food products with Atova’s Regulatory Scientist & Toxicologist, Fernando Rivero Pino, among the authors.   


The paper considers whether traditional whole-food animal studies are always the most scientifically appropriate approach for cultivated foods, and explores how a tiered, weight-of-evidence framework could support robust and proportionate safety assessments.   


Importantly, the discussion is not about lowering the standard for food safety. Rather, it considers how the evidence used in a safety assessment can be scientifically relevant, fit for purpose, and proportionate to the characteristics and risks of the product. For the cultivated food industry, this is an important regulatory science discussion. The approach taken to the safety assessment can have a significant impact on regulatory strategy, development timelines, and the evidence needed to support market authorisation.   


It’s great seeing Fernando’s toxicology and regulatory expertise contributing to this work, alongside experts from across the cultivated food, regulatory science and academic communities. It’s a valuable contribution to the ongoing discussion around how safety assessment approaches can evolve alongside new food technologies.   


📖 Read the full paper here. 



New Foods RegLab Partner 

We are happy to share that ATOVA Regulatory Consulting is the regulatory partner of the first New Foods RegLab, a pioneering project by the think-and-do tank, Ministry of Future Affairs.


Are you at an early stage of preparing a novel-food dossier for the EU? The application takes about ten minutes.

  • The New Foods RegLab tests the novel-food guidance from a user perspective!

  • It tests in practice how applicants and assessors can learn from each other: ten companies, two days, and anonymised learnings shared with EFSA, the European Commission and other relevant stakeholders in the European institutions and beyond.

  • Learn more about the benefits for participants on the Ministry of Future Affairs website!


❗ Impact: Inform the future of the novel-food pre-submission advice in the EU.

👉 Apply by 30 November 2026! Find out more and apply here.



EFSA Updates


Validated Dossiers

The following dossier published on Open EFSA was validated in October.

Name of Product

Dossier Received by EFSA

Validated

Time until validation

21/01/2026

25/10/2026

approx. 13.7 months


Dossiers Considered Non-Valid and Withdrawn Dossiers

There were three dossiers considered non-valid or withdrawn in October. Out of these three dossiers, two were declared as non-valid and one was withdrawn. 

Name of Product

Dossier Received by EFSA

Declared Non-Valid / Withdrawn

Time until Non-Valid / withdrawn

25/08/2025

12/10/2026

approx. 13.7 months

22/04/2024

12/10/2026

approx. 29.7 months

21/08/2025

12/10/2026

approx. 13.7 months


EFSA Public Consultations

Three EFSA novel food opinions, including a traditional food from a third country were published on Open EFSA during October. 

  • Safety of roasted and ground kernels of an edible variety of Jatropha curcas L. (Xuta) as a traditional food from a third country pursuant to Regulation (EU) No 2015/2283 

    • Received on 06/03/2024, validated on 02/12/2024 and opinion published on 28/10/2026 (approximately 31.7 months from receipt to publication)

    • EFSA issued a positive scientific opinion on the safety of roasted and ground kernels of an edible variety of Jatropha curcas L., known as Xuta, as a traditional food from a third country. Published on 28 October 2026, the opinion assessed their proposed use in grain-based products and soups, drawing on a history of consumption spanning more than 25 years in Mexico. Additional analytical data and controls to prevent mixing with non-edible kernels resolved earlier safety objections, particularly concerning phorbol esters. EFSA concluded that the product is safe under the proposed conditions of use and that its consumption is not nutritionally disadvantageous. 

  • Safety of benfotiamine as a Novel food pursuant to Regulation (EU) 2015/2283 and the bioavailability of benfotiamine as a source of thiamin in the context of Directive 2002/46/EC on food supplements 

    • Received on 22/02/2024, validated on 07/03/2025 and opinion published on 09/10/2026 (approximately 31.5 months from receipt to publication)  

    • EFSA could not establish the safety of benfotiamine as a novel food and therefore did not issue a positive safety conclusion. The opinion assessed chemically synthesised benfotiamine as a source of thiamin (vitamin B1) in food supplements for adults at up to 300 mg/day. Key gaps included insufficient product characterisation, unresolved questions concerning small particles and nanoparticles, and inadequate information on metabolic fate, potential bioaccumulation and long-term effects. Although EFSA confirmed that benfotiamine is a bioavailable source of thiamin, the available data were also insufficient to derive a conversion factor for labelling purposes. 

  • Safety of frozen paste from blanched, whole migratory locust (Locusta migratoria) as a novel food pursuant to Regulation (EU) 2015/2283 

    • Received on 20/06/2018, validated on 02/10/2024 and opinion published on 05/10/2026 (approximately 99.5 months from receipt to publication)  

    • EFSA issued a positive scientific opinion on the safety of frozen paste made from blanched, whole migratory locusts (Locusta migratoria) as a novel food. The opinion assessed its proposed use as an ingredient in various food products for the general population. EFSA concluded that the paste is safe under the proposed conditions of use and that its consumption is not nutritionally disadvantageous. However, the Panel highlighted the potential for allergic reactions, including in people allergic to crustaceans, mites or molluscs, and noted that allergens from the insects’ feed, such as soy and gluten, could be present in the final product. 

       

  • EFSA concluded that extending the use of glycolipids (E 246) as a food additive to 11 additional food categories raised no safety concern. Adopted on 17 September and published on 23 October 2026, the opinion covered uses including cheese rinds, pomegranate arils, meat surfaces, alcoholic beverages and liquid food supplements. This was an extension of an existing food additive authorisation. 

  • The key package comprised proposed maximum and typical use levels and combined exposure estimates covering existing and proposed uses. EFSA recalculated exposure using FAIM 3.0, including a separate scenario for supplement consumers. The highest estimated exposure was 6.2 mg/kg body weight/day, below the established acceptable daily intake (ADI) of 10 mg/kg body weight/day. 

  • The underlying safety evidence came from the 2021 assessment of glycolipids produced by fermentation of Dacryopinax spathularia. That package included toxicokinetic and genotoxicity data, 90-day oral toxicity studies in rats and dogs, and reproductive and prenatal developmental toxicity studies in rats. EFSA established the ADI from NOAELs of 1,000–1,423 mg/kg body weight/day. The 2026 extension therefore built on an established toxicological assessment. 

  • Approximately seven months elapsed between dossier receipt in February 2026 and opinion adoption. This is elapsed time, rather than a verified measure of active assessment time. Publication followed approximately eight months after receipt. 

 

  • EFSA did not substantiate the Article 13(5) health claim that Appethyl® prolongs satiety and reduces cravings after a meal. The application concerned 5 g/day of a spinach extract enriched in thylakoids. The supporting package included product characterisation, human intervention evidence and two unpublished study reports. EFSA accepted that the ingredient was sufficiently characterised. 

  • The central problem was failure to identify a single beneficial physiological effect: changes in appetite ratings are not beneficial in themselves. The same evidence had previously failed to establish a weight-loss effect. Despite two information requests and a clarification meeting, the applicant proposed multiple outcomes and mechanisms involving glucose, insulin and insulin resistance without resolving this issue. Consequently, EFSA could not proceed to establish a cause-and-effect relationship for the claim. 

  • The timeline was approximately 9.5 months from receipt to adoption, or 133 days from validation, including two clock stops.


EFSA Guidance on default values and uncertainty factors 

On 27 October 2026, EFSA published updated guidance on default values and uncertainty factors, replacing its 2012 guidance. It distinguishes between default values, which represent typical parameters such as body weight, and uncertainty factors, which address uncertainties when translating available evidence into conclusions on human safety. EFSA emphasises that robust, relevant data should take precedence over defaults and that departures from the recommended factors require scientific justification. 

 

For novel food applicants, a particularly relevant aspect is the continued use of an overall uncertainty factor of 100 for differences between experimental animals and humans and variability within the human population, together with a factor of two for extrapolation from subchronic to chronic exposure. The latter applies where the subchronic study is sufficiently reliable; it is inappropriate where kinetic data indicate bioaccumulation or a long half-life. Additional factors may be needed for database deficiencies or particular toxicological concerns, while obtaining additional data is the preferred approach to addressing inadequate evidence. 

 

These recommendations support the approach already described in EFSA’s 2024 novel food guidance, which usually applies a combined uncertainty factor of 200 (10 × 10 × 2) to a reference point derived from a 90-day toxicity study. In a margin of exposure (MoE) assessment, the reference point—such as a no-observed-adverse-effect level (NOAEL) or the lower confidence bound of a benchmark dose (BMDL)—is divided by estimated human intake, expressed in matching units. An MoE of 200 therefore represents the usual target under those assumptions, with a different margin possible where scientifically justified. The 2026 guidance reinforces an existing approach; it does not introduce a new universal MoE requirement for all novel foods. 

 

For illustration, a reference point of 1,000 mg/kg body weight/day and estimated intake of 5 mg/kg body weight/day would give an MoE of 200. For applicants, the practical implication is to consider anticipated exposure alongside toxicology study design early in development. Where a 90-day study is needed, dose selection should support a meaningful comparison with proposed human intake, while recognising the nutritional constraints of testing whole foods. Meeting the numerical margin remains one part of the overall safety assessment. Read in full here.

 

EFSA Working Group and Panel Plenary Meetings 

The 181st Working Group meeting on Novel Foods took place on 13-15 October. The minutes for this meeting are now available to view. This included draft opinions on Hydroxytyrosol, Serratiopeptidase, Arachidonic acid-rich oil from the fungus Mortierella alpina, Serratiopeptidase (Serratia marcescens), LPC-rich oil extract of Antarctic krill, Coffee cherry pulp, and duck cells from cell culture. Read the minutes here.

 

The agenda from the 173rd Panel Plenary meeting of the Scientific Panel on Nutrition, Novel foods and Food Allergens is available online. This meeting is due to be held on 25-27 November, with draft opinions up for discussion on the evaluation of hydroxycitric acid (HCA) and plant preparations containing HCA, plant preparations containing berberine, and preparations from the fruits of sweet and bitter fennel. The agenda is available here.  

 

The 23rd Plenary Meeting of EFSA’s Panel on Food Enzymes (FEZ) was held on 6–8 October 2026. The agenda for this meeting is available to view here. 



European Commission Updates

 

Standing Committee on Plants, Animals, Food and Feed (SCoPAFF) Meetings

The Novel Food and Toxicological Safety meeting took place on 25th September. The agenda for this meeting is available here. The next meeting for the SCoPAFF General Food Law meeting is provisionally due to take place on 16th October. 

 

Article 4 Novel Food Consultations

There were three Article 4 novel food consultation outcomes published in October.

 

The outcome of an Article 4 novel food consultation concerning defatted olive pulp fruit powder has been published. The consultation, submitted to the Spanish Agency for Food Safety and Nutrition O.A (AESAN O.A), concerns a powder, with a with a granulometry of 500 µm, obtained from the dehydration of the pulp of the olive fruit (Olea europaea L.). This is deboned and defatted from the olive oil production process, with the powder containing the same components naturally present in the olive but in different proportions. The resulting powder is intended for use as a food supplement.  

✅  Conclusion: Not Novel  The ingredient is derived from the fruit of the olive tree (Olea europaea L.), which has a history of significant consumption in the European Union before 15 May 1997. The fruit of this plant species is also on the positive list of plants authorised for use in food supplements in several Member States. Additionally, the product is obtained using conventional processing methods and does not result in any new compounds being formed compared to the natural composition of the olive.  

 

Sweet cicely (Myrrhis odorata) – shoots and leaves  The outcome of an Article 4 Novel Food consultation concerning sweet cicely (Myrrhis odorata (L.) Scop.) has been published. The consultation, submitted to the Swedish Food Agency, concerns the plant’s shoots and young leaves, which are intended for use as fresh greens or herbs, or in products containing fresh vegetables.  

✅ Conclusion: Not Novel  It was concluded that the shoots and leaves of sweet cicely are not novel foods, based on evidence of significant consumption within the European Union before 15 May 1997. Historical and ethnological documents from the 18th and 19th centuries describe their use in fresh greens and cooked dishes across parts of Europe. Swedish sales catalogues from 1882 also listed the plant’s seeds for kitchen gardening.   


S-adenosyl-L-methionine disulfate tosylate (SAMe salt form)  The Lithuanian Institute of Hygiene assessed S-adenosyl-L-methionine disulfate tosylate, a salt form of S-adenosyl-L-methionine (SAMe), a naturally occurring compound involved in human metabolism. This chemically defined derivative of SAMe is set to be used in food supplements and may be produced through fermentation or chemical synthesis.  

✅ Conclusion: Not Novel in food supplements  Following a reassessment of the available information, Lithuania concluded that this specific salt form of SAMe is not novel when used in food supplements. The decision considered an earlier confirmation from Italy that the substance was not novel in food supplements, alongside additional technical and historical documentation and discussions between Member States. Importantly, this conclusion applies specifically to S-adenosyl-L-methionine disulfate tosylate and does not automatically extend to other SAMe salt forms.  


Spain launches public consultation to define quality standard for kefir 

Spain’s Ministry of Agriculture, Fisheries and Food opened a public consultation on a draft Royal Decree establishing a national quality standard for kefir. The initiative comes amid a 120% increase in fermented product consumption since 2020, highlighting the need for a harmonised regulatory framework. The proposed standard aims to define kefir and establish requirements for its production, marketing, denomination and labelling, ensuring clear and accurate consumer information while providing greater legal certainty for producers using different manufacturing methods. Read more here.



FSA Board Meeting 

The FSA Board held a meeting on 16th September 2026. The agenda for this meeting included discussions on the FSA sanitary and phytosanitary programme, CBD novel food applications, future of food regulation report, meat charging discount, FSA science update, and committee reports. This meeting is now available to watch online.  

 

Advisory Committee on Novel Foods and Processes (ACNFP) 

The ACNFP subcommittee on Products of Genetic Technologies (PGT) met on 20th October. The agenda can be found here.

 

The next ANCFP meeting is scheduled for 18th November 2026. The Agenda can be accessed here. Of note, they will discuss the human equivalent lactoferrin dossier.FSA




FDA proposes cadmium action levels and new chemical hazard control guidance under Closer to Zero initiative

The FDA announced new measures under its Closer to Zero initiative, aimed at reducing dietary exposure to heavy metals, including arsenic, cadmium, lead, and mercury, in foods intended for babies and young children. As part of these efforts, the FDA published draft guidance proposing action levels for cadmium in processed foods intended for babies and young children (Read here). These levels are intended to help manufacturers reduce cadmium concentrations through appropriate control measures. Comments on the draft guidance may be submitted until December 22, 2026. 


Additionally, the FDA released draft guidance on the control of chemical hazards under 21 CFR Part 117 (Read here), providing recommendations for identifying, evaluating, and controlling chemical contaminants in human foods through current good manufacturing practices, preventive controls, and supply-chain measures. Comments may be submitted until January 21, 2027. 


The FDA also announced a webinar scheduled for November 16, 2026, to discuss these updates and other food chemical safety initiatives. Link to the webinar registration, here.   

 

FDA finalises guidance on identity and safety information for New Dietary Ingredient Notifications (NDIN) 

The FDA has updated its recommendations for preparing New Dietary Ingredient Notifications (NDINs), introducing greater flexibility in how manufacturers and distributors demonstrate the identity and safety of new dietary ingredients (NDIs). 

 

The final guidance (Read here) replaces Sections VI.A, VI.B and VI.C of the 2016 revised draft guidance, covering ingredient identity and characterisation, history of use or other evidence of safety, and the scientific basis for concluding that an NDI is reasonably expected to be safe. 

 

Key changes include replacing separate safety assessments with a single integrated safety narrative, adopting a more flexible, risk-based approach to toxicological testing, recognising alternative testing methodologies (including in vitro and in silico methods), and allowing greater flexibility in substantiating safety through historical use data. The guidance also clarifies expectations for ingredient characterisation, manufacturing controls, analytical verification and safety calculations. 

 

Although non-binding, the guidance reflects FDA's current recommendations. Manufacturers and distributors preparing NDINs should review their dossier preparation procedures accordingly. The FDA will continue finalising the remaining sections of the 2016 draft guidance, and public comments may be submitted at any time under docket FDA-2025-D-6501 

 

The FDA has published the 2026 edition of the FDA Food Code, a model framework designed to support food safety and public health across US retail and food service settings. Updated every two years, the Food Code reflects developments in food safety science, regulatory practice and emerging industry trends. 

 

The 2026 edition introduces several updates, including requirements for written employee illness policies, an alternative cooling process for certain foods, and provisions for double gloving in specific circumstances. It also provides updates covering areas such as allergen cross-contact, food donations, specialty mushroom safety, dehydration and freeze-drying, mobile food establishments and vending machine controls. 

 

FDA finalises guidance on identity and safety information for New Dietary Ingredient Notifications (NDIN) 

The GRAS notice inventory was recently updated to include 21 new notifications all of which are pending an FDA response: 

  • GRN 1360 - Lactobacillus gasseri strain CECT 30648 - Intended for use as an ingredient in conventional foods at levels up to 10^10 CFU per serving  

  • GRN 1359 - Bifidobacterium animalis subsp. lactis CCTCC M 2013336 - Intended for use as an ingredient in conventional foods at a level up to 1.02 × 10^11 CFU per serving  

  • GRN 1358 - Lacticaseibacillus paracasei subsp. paracasei GDMCC 60960 - for use as an ingredient in conventional foods at a level up to 1 × 10^10 CFU per serving  

  • GRN 1357 - Yeast protein produced by a non-genetically engineered Saccharomyces cerevisiae strain - Intended for use as a food ingredient, source of protein, and nutrient supplement 

  • GRN 1356 - Rebaudioside M produced by enzymatic treatment of rebaudioside A purified from the leaves of Stevia rebaudiana (Bertoni) Bertoni - Intended for use as a general-purpose sweetener in foods  

  • GRN 1355 - Rebaudioside M9 produced by enzymatic treatment of rebaudioside A purified from the leaves of Stevia rebaudiana (Bertoni) Bertoni - Intended for use as a general-purpose sweetener in foods  

  • GRN 1354 - Rebaudioside M produced by enzymatic treatment of rebaudioside A purified from the leaves of Stevia rebaudiana (Bertoni) Bertoni - Intended for use as a general-purpose sweetener in foods  

  • GRN 1353 - L-ergothioneine produced by Escherichia coli strain ERG2201 expressing genes encoding enzymes from Methylobacterium aquaticum, Trichoderma reesei, and Mycolicibacterium smegmatis - Intended for use as an ingredient in a variety of food categories  

  • GRN 1351 - Heat-killed biomass of Xanthobacter sp. DSM 34079 - Intended for use as a source of protein in a variety of food categories 

  • GRN 1350 - Rebaudioside M produced by enzymatic treatment of rebaudioside A purified from the leaves of Stevia rebaudiana (Bertoni) Bertoni - Intended for use as a general-purpose sweetener in foods  

  • GRN 1348 - β-casein protein preparation - Intended for use as a source of protein, stabilizer, emulsifier, texturizer, coagulant, water binder, and/or flavoring agent at levels up to 50%  

  • GRN 1347 - Lactobacillus plantarum KCTC 13101BP - Intended for use as an ingredient in conventional foods at levels up to 5 × 10^9 CFU per serving). 

  • GRN 1346 - Saccharomyces pastorianus BY-1198 expressing a gene encoding an α-acetolactate decarboxylase enzyme from Acetobacter aceti - Intended for use at a level up to 2.50 × 10^6 cells/mL/degree Plato of wort in the production of beer 

  • GRN 1345 - Bacillus subtilis NCIMB 30283 - Intended for use as an ingredient in conventional food at levels up to 1 x 10^9 CFU per serving  

  • GRN 1344 - L-theanine (chemically synthesized) - Intended for use as an ingredient at maximum levels ranging from 1 to 125 mg/g  

  • GRN 1343 - L-ergothioneine produced by Escherichia coli CGMCC 24897, expressing enzymes from Trichoderma reesei ATCC 13631 - Intended for use as an ingredient in a variety of food categories 

  • GRN 1342 - D-psicose - Intended for use as an ingredient in a variety of food categories 

  • GRN 1340 - L-ergothioneine produced by Escherichia coli K12 MG1655, expressing enzymes from Mycolicibacterium smegmatis, Methylobacterium pseudosasicola, Microcoleus sp. PCC 7713, and Neurospora crassa - Intended for use as an ingredient in a variety of food categories 

  • GRN 1339 - L-ergothioneine produced by Escherichia coli EG38, expressing enzymes from Mycolicibacterium smegmatis, Schizophyllum commune H4-8, and Claviceps purpurea - Intended for use as an ingredient in various food categories 

  • GRN 1338 - Brazzein preparation produced by a genetically engineered strain of Komagataella phaffii BG12 expressing a gene encoding for brazzein from Pentadiplandra brazzeana - Intended for use as a general-purpose sweetener in foods at levels consistent with cGMP 

  • GRN 1337 - Heat-killed Lacticaseibacillus paracasei 327 - Intended for use as an ingredient in specified foods and beverages up to 25 mg per serving.  

 

US-Food Additive Petition  & Color Additive Petition Updates 

  • FAP-1A4829 - Vitamin D2 inactive bakers yeast (UV-treated Saccharomyces cerevisiae) – FDA’s final amendment to 21 CFR 172.383 permits specified uses as a vitamin D2 source. The order was published and effective on 25 September 2026; the objection deadline was 26 October 2026. 

 

US-Animal Food Ingredient Consultations (AFIC) 

  • 0004 – Pea solubles - FDA completed its consultation in a letter dated 25 September 2026. The assessed use is as a pelleting aid or binder incorporated into canola meal before pelleting at up to 2% for use in animal food.  U.S.



Canada

On 22nd October, Health Canada published a proposal to permit the digestible indispensable amino acid score (DIAAS) method  to determine protein quality for most foods and to allow two in vitro digestibility assays within the protein digestibility corrected amino acid score (PDCAAS) approach. The proposal matters for protein content claims and compositional requirements, potentially expanding the methods available to substantiate the nutritional quality of innovative proteins. Comments are invited until 20th  January 2027. Read more here.

 

Switzerland 

The list of applications submitted to the Federal Food Safety and Veterinary Office (FSVO) was updated on 16th October, which is available to view here. The classifications and authorisations by the FSVO was also updated on the 29th October with four assessments currently in progress including Urolithin A, Bos Taurus (cell-cultured muscle tissue), Bos Taurus (cell-cultured adipose tissue), and Anas platyrhynchos domesticus. The list is available here.

 

There were two novel food status classifications published in October by the Federal Food Safety and Veterinary Office (FSVO). These were:

  • Alcoholic extract of the root of Withania somnifera L. - concluded as a novel food - Although all parts of the plant Withania somnifera L. are classified in the EU as

    ‘not novel in food supplements’, this classification does not apply directly to extracts of the plant or of individual parts of the plant.

  • Hydroalcoholic extract of the aerial parts of Passiflora incarnata L. - concluded as a novel food - This was extracted with a 70:30 water:ethanol solution and contains specific phytochemicals and other constituents of Passiflora incarnata L. in concentrated form, obtained through a defined extraction process, after which it no longer corresponds to the original composition of the root. Based on the information currently available to the FSVO, there is no evidence to suggest

    that this specific hydroalcoholic extract of the aerial parts of Passiflora incarnata L. was used as a food for human consumption to a significant degree in Switzerland or a Member State of the EU prior to 15 May 1997.

 

Thailand

Consultation on specific GMP requirements for cultivated foods 

On 19th October, the Thai FDA published a consultation on dedicated manufacturing requirements for foods derived from animal cell culture. The draft covered cell banks, proliferation and differentiation, bioreactors, aseptic controls, residue monitoring, production personnel and manufacturing premises. It also proposed equivalent manufacturing-standard documentation for imports. Comments are invited until 30 November 2026. This represented development of production controls rather than a product authorisation.  Read more here.

 

Australia New Zealand

 

On the 6th October the Food Standards Australia New Zealand (FSANZ) Board held an extraordinary meeting to discuss standards matters for decision on application A1341. The board approved the application to permit cell-cultured duck biomass to be used as a food ingredient, with the board being satisfied that the available scientific evidence supports the safety of the approved food at the assessed levels of consumption. Read more here. FSANZ notified the approval to the Food Ministers’ Meeting on 13 October. Ministers have 60 days to request a review or advise that no review is sought. 

 

India 

The Food Safety and Standards Authority of India (FSSAI) has launched a new Start-Up Cell designed to help emerging food businesses, D2C brands, and cloud kitchens navigate food safety regulations and seek guidance on regulatory queries. The initiative features a dedicated email helpdesk (startupcell@fssai.gov.in) and weekly online interaction sessions every Wednesday to provide real-time regulatory guidance and cross-division support, empowering foodpreneurs to bring new products to market with confidence. Find out more here.  

 

US food tech startup secures regulatory approval  

US-based food tech firm BMC Ingredients has secured regulatory approval from the FSSAI for its Rhiza mycelium ingredient, marking its entry into the Indian market which is targeted for Q2 2027. India marks the fourth international market approval for Rhiza following the US, Canada, and Singapore. 

 

 

Abu Dhabi 

On 8th October 2026, Abu Dhabi announced a guideline for tasting and sensory evaluation of novel foods before full UAE market approval. It covers technologies including cell-cultivated foods and precision fermentation products. Trials take place in a controlled research environment, subject to safety assessment, testing and participant protections, with ADAFSA reviewing applications and issuing the required trial approvals. Read more here.lth



Have any questions about how these developments could affect your products or regulatory strategy? Get in touch with the Atova team – we’re here to help you navigate the evolving regulatory landscape with confidence. 



Subscribe to keep up-to-date with all the major regulatory updates & news:



 
 
 

Comments


bottom of page